Complications of Campylobacter Infection

Immediate Clinical Complications

Campylobacter infections can progress beyond self-limited gastroenteritis to cause serious acute complications, including bacteremia, toxic megacolon, intestinal perforation, and rectal prolapse, particularly in immunocompromised patients 1, 2
Severe abdominal pain that may mimic appendicitis is characteristic of Campylobacter enteritis and should prompt consideration of imaging to rule out surgical complications 1, 2
Toxic megacolon can develop in rare cases and requires urgent detection via abdominal ultrasound or X-ray 1, 2
Intestinal perforation rarely occurs but can be identified by plain abdominal X-ray 1, 2
Ileus may complicate severe disease and warrants imaging evaluation 1, 2
Rectal prolapse has been documented as a rare acute complication 1, 2
Bacteremia occurs particularly in immunocompromised patients and pregnant women, potentially leading to intrauterine infection, abortion, stillbirth, or early neonatal death during pregnancy 1, 2

Campylobacter jejuni is the most frequently identified infectious trigger of Guillain-Barré syndrome worldwide, accounting for approximately 30% of all GBS cases 3, 4
Geographic variation in GBS risk is substantial, with antecedent C. jejuni infection detected in 60-70% of GBS patients in regions like Curaçao, China, and Bangladesh, compared to 30-32% in other countries 3
Public health interventions targeting Campylobacter contamination in poultry have demonstrated effectiveness, with New Zealand achieving a 52% decline in campylobacteriosis and simultaneous 13% reduction in GBS hospital admissions 3

Reactive arthritis develops in approximately 2% of Campylobacter enteritis cases and causes impaired joint movement that can persist long-term 1, 2
Clinical presentation includes inflammation of various joints following the acute gastroenteritis episode 1, 2

Campylobacter infection is an established trigger for post-infection IBS, with animal models demonstrating long-lasting changes in gut microbiota, intestinal motility, and stool consistency 5
Pathophysiological mechanisms include persistent alterations in gut microbiota composition reminiscent of small intestinal bacterial overgrowth and changes in interstitial cells of Cajal (ICC) counts 5
Treatment approach: Prophylactic rifaximin has shown benefit in ameliorating changes in stool consistency in animal models 5
Patient education is the first step in management, with reassurance that symptoms are likely to improve or resolve over time, particularly with viral-associated PI-IBS 5

Antibiotic therapy with azithromycin should be initiated within 72 hours of symptom onset in severe cases and all immunocompromised patients to reduce symptom duration and potentially prevent complications 6
Imaging evaluation (abdominal ultrasound or CT scan) is warranted when clinical deterioration occurs to detect thickened bowel wall, ileus, or toxic megacolon 1, 2
Immunocompromised patients require systemic antibiotic treatment even for mild infections due to risk of bacteremia and systemic spread 1, 2, 6
Monitor for neurological symptoms (ascending weakness, areflexia) in the weeks following acute infection, as GBS typically develops 1-3 weeks post-infection 3
Assess for joint symptoms indicating reactive arthritis in patients with persistent musculoskeletal complaints 1, 2
Evaluate persistent gastrointestinal symptoms beyond 10-14 days for possible PI-IBS or other chronic sequelae 5, 6